3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
14
Neoplasms
7
Endometrial Neoplasms
6
Lung Neoplasms
5
Melanoma
4
Head and Neck Neoplasms
4
Colonic Neoplasms
4
Esophageal Neoplasms
3
Uterine Cervical Neoplasms
2
Solitary Pulmonary Nodule
2
Multiple Pulmonary Nodules
2
Lymphedema
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Uterine Neoplasms
1
Thyroid Neoplasms
1
Suspected Central Nervous System Tumors
1
Stomach Neoplasms
1
Skull Base Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Pediatric Patients With Solid Tumors
1
Interventions
Cisplatin
33
Radiotherapy
23
Cetuximab
18
Paclitaxel
14
Docetaxel
14
pembrolizumab
13
Carboplatin
12
Fluorouracil
10
Radiotherapy, Intensity-Modulated
8
Nivolumab
8
Drug Therapy
7
Erlotinib Hydrochloride
6
Panitumumab
5
dacomitinib
4
Radiation
4
Methotrexate
4
Esophagectomy
4
130-nm albumin-bound paclitaxel
4
durvalumab
3
ON 01910
3
Leucovorin
3
Gemcitabine
3
Chemoradiotherapy
3
vandetanib
2
palbociclib
2
osimertinib
2
nedaplatin
2
fludarabine
2
cabazitaxel
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Squamous Cell
×
Indocyanine Green
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled